J
Joachim M. Baehring
Researcher at Yale University
Publications - 156
Citations - 7422
Joachim M. Baehring is an academic researcher from Yale University. The author has contributed to research in topics: Nivolumab & Temozolomide. The author has an hindex of 29, co-authored 142 publications receiving 5711 citations. Previous affiliations of Joachim M. Baehring include Harvard University & Yale Cancer Center.
Papers
More filters
Journal ArticleDOI
Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma
Josep Dalmau,Erdem Tüzün,Hai-Yan Wu,Jaime Masjuan,Jeffrey E. Rossi,Alfredo Voloschin,Joachim M. Baehring,Haruo Shimazaki,Reiji Koide,Dale King,Warren P. Mason,Lauren H Sansing,Marc A. Dichter,Myrna R. Rosenfeld,David A. Lynch +14 more
TL;DR: The autoantigens of a new category of treatment‐responsive paraneoplastic encephalitis are reported, and it is proposed that this category should be combined with existing treatment-responsive encephalopathy categories.
Journal ArticleDOI
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark,E. Zeynep Erson-Omay,Akdes Serin,Jun Yin,Justin Cotney,Koray Özduman,Timucin Avsar,Jie Li,Phillip B. Murray,Octavian Henegariu,Saliha Yilmaz,Jennifer Moliterno Günel,Geneive Carrión-Grant,Baran Yılmaz,Conor Grady,Bahattin Tanrıkulu,Mehmet Bakırcıoğlu,Hande Kaymakçalan,Ahmet Okay Caglayan,Leman Sencar,Emre Ceyhun,A. Fatih Atik,Yasar Bayri,Hanwen Bai,Luis Kolb,Ryan Hebert,S. Bulent Omay,Ketu Mishra-Gorur,Murim Choi,John D. Overton,Eric C. Holland,Shrikant Mane,Matthew W. State,Kaya Bilguvar,Joachim M. Baehring,Philip H. Gutin,Joseph M. Piepmeier,Alexander O. Vortmeyer,Cameron Brennan,M. Necmettin Pamir,Turker Kilic,Richard P. Lifton,Richard P. Lifton,James P. Noonan,Katsuhito Yasuno,Murat Gunel +45 more
TL;DR: Genetic analysis of 300 meningiomas, the most common primary brain tumors, leads to the discovery of mutations in TRAF7, a proapoptotic E3 ubiquitin ligase, in nearly one-fourth of all mening iomas, suggesting avenues for targeted therapeutics.
Journal ArticleDOI
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon,Alba A. Brandes,Antonio Omuro,Paul Mulholland,Michael Lim,Antje Wick,Joachim M. Baehring,Manmeet Ahluwalia,Patrick Roth,Oliver Bähr,Surasak Phuphanich,Juan Manuel Sepúlveda,Paul de Souza,Solmaz Sahebjam,Michael Carleton,Kay Tatsuoka,Corina Taitt,Ricardo Zwirtes,John Sampson,Michael Weller +19 more
TL;DR: Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.
Journal ArticleDOI
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro,Gordana Vlahovic,Michael Lim,Solmaz Sahebjam,Joachim M. Baehring,Timothy F. Cloughesy,Alfredo Voloschin,Shakti Ramkissoon,Keith L. Ligon,Robert Latek,Ricardo Zwirtes,Lewis C. Strauss,Prashni Paliwal,Christopher T. Harbison,David A. Reardon,John H. Sampson +15 more
TL;DR: Nivolumab monotherapy was better tolerated than nivolumsab + ipilimumab; the tolerability of the combination was influenced by ipilicumab dose.
Journal ArticleDOI
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James M. Schuster,Rose Lai,Rose Lai,Lawrence Recht,David A. Reardon,David A. Reardon,Nina Paleologos,Nina Paleologos,Morris D. Groves,Morris D. Groves,Maciej M. Mrugala,Randy L. Jensen,Joachim M. Baehring,Andrew E. Sloan,Gary E. Archer,Darell D. Bigner,Scott Cruickshank,Jennifer Green,Tibor Keler,Thomas A. Davis,Amy B. Heimberger,John H. Sampson +21 more
TL;DR: Rindopepimut as discussed by the authors is designed to generate a specific immune response against EGFRvIII+ tumor cells, an approach which may be particularly relevant for glioblastoma, where diffuse infiltration of tumor into healthy white matter presents a treatment challenge.